எம்மா ரோப்பர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from எம்மா ரோப்பர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In எம்மா ரோப்பர் Today - Breaking & Trending Today

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer


(2)
Regulatory News:
Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC) met one of the primary endpoints, demonstrating significant improvement in progression-free survival (PFS) at the planned primary analysis. A prespecified interim analysis for the second primary endpoint of overall survival (OS), conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination of cabozantinib and atezolizumab, but did not reach statistical significance. Based on the preliminary OS data, Exelixis anticipates that the probability of reaching statistical significance at the time of the final analysis is low. The trial will continue as planned to the final analysis of OS; results are anticipated in early 20 ....

France General , United States , Hong Kong , United Kingdom , New Zealand , South Korea , United Arab Emirates , Dominican Republic , Saudi Arabia , Russian Federation , Susan Hubbard , Michaelm Morrissey , Lindsay Treadway , Gemma Roper , Ipsen Euronext , Daiichi Sankyo Company , Drug Administration , Takeda Pharmaceutical Company , Exchange Commission , Exelixis Inc , International Agency For Research On Cancer , Public Affairs , European Union , Roche Group , Regulatory News , Exelixi President ,

Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results


Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results
1
Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Participation in the collaboration will provide Ipsen with access to full trial data to support potential future regulatory submissions
Disclaimer: Intended for international media and investor audiences only
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has exercised its option to collaborate with Exelixis, Inc. (Exelixis) in the pivotal COSMIC-311 Phase III trial. COSMIC-311 is evaluating Cabometyx
(cabozantinib) 60 mg versus placebo in people living with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies. ....

France General , United States , Hong Kong , United Kingdom , New Zealand , South Korea , Dominican Republic , Saudi Arabia , Russian Federation , Giovanni Asta , Howard Mayer , Gemma Roper , Ipsen Euronext , Head Of Research , American Society Of Clinical Oncology , Drug Administration , Takeda Pharmaceutical Company , Global Franchise Communications , European Thyroid Association Guidelines For The Treatment , Exelixis Inc , Clinical Oncology , Annual Meeting , Executive Vice President , Breakthrough Therapy Designation , Product Characteristics , Takeda Pharmaceutical Company Limited ,

More than £1 million raised for injured Patterdale mountain rescuer Chris Lewis


More than £1 million raised for injured Patterdale mountain rescuer Chris Lewis
Chris Lewis
More than £1 million has been raised for the Patterdale mountain rescue volunteer critically injured following a 150-metre fall in February – but much more is still needed.
Chris Lewis, 60, remains in hospital after sustaining life-altering injuries during a callout to a camper suffering from chest pains at Red Screes, near Kirkstone Pass, during lockdown.
A fund set up by Lake District Search and Mountain Rescue Association on JustGiving to help pay for Chris’ medical needs and his family’s wellbeing, has now reached £1,029,009.86.
The sum is made up of £856,939.12 which has been directly donated and an estimated £172,214.74 of Gift Aid, which can be claimed back from Her Majesty’s Revenue and Customs. ....

United Kingdom , Lake District , Kirkstone Pass , Chris Lewis , Gemma Roper , Mountain Rescue Association On Justgiving , Penrith Rugby Club , Red Screes , Lake District Search , Mountain Rescue Association , Gift Aid , Her Majesty , Bob Graham Round , ஒன்றுபட்டது கிஂக்டம் , ஏரி மாவட்டம் , கிறிஸ் லெவிஸ் , எம்மா ரோப்பர் , பென்ரித் ரக்பி சங்கம் , ஏரி மாவட்டம் தேடல் , மலை மீட்பு சங்கம் , பரிசு உதவி , அவள் கம்பீரம் , பாப் கிரஹாம் சுற்று ,